Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026, in Padua, Italy. The event, hosted by the University of Padova, will focus on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is making significant clinical progress.
AEPC, founded in 1963, is the world’s largest association in congenital cardiology, with over 1,000 specialists from 32 European countries and beyond. The meeting’s scientific program centers on technologies that are reshaping pediatric cardiology, including AI-driven imaging solutions. Ventripoint will share a booth with its European distributor, AngioPro, to engage with clinicians and highlight the capabilities of VMS+™, particularly for monitoring cardiac function over time in congenital heart disease (CHD) patients.
The importance of longitudinal assessment is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for ventricular function assessment (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554). Ventripoint’s VMS+™ 4.0, the latest release, is designed to streamline workflows and provide accurate volumetric cardiac measurements equivalent to MRI at the point of care, supporting clinical decision-making from a patient’s first echocardiogram.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients. The system is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada.
